This range in RASD1 expression likely stems from inherent genetic and molecular distinctions characteristic of each specific cancer type, as well as the heterogeneity of tumors like pancreatic cancer, renal cancer, and glioblastoma [24,25,26]. The gene discussed is RASD1; the disease is glioblastoma.